NRAS and melanoma: Notably, the efficacy of this combinatorial treatment in melanoma cells is not influenced by BRAF, NRAS, or NF1 mutational status, opening the possibility of using this combinatorial therapy to treat melanoma expressing high levels of GLI1 and ERK5, irrespective of their mutational status, and, possibly, other tumours with active ERK5 and HH-GLI pathways.